NOVARTIS AG's Net Worth
$1.34 Billion
Who is NOVARTIS AG?
NOVARTIS AG has an estimated net worth of $1.34 Billion. This is based on reported shares across multiple companies, which include Cellular Biomedicine Group, Inc., Poseida Therapeutics, Inc., Akouos, Inc., Forma Therapeutics Holdings, Inc.,, Galera Therapeutics, Inc., BICYCLE THERAPEUTICS plc, AveXis, Inc., Surface Oncology, Inc., Homology Medicines, Inc., Intellia Therapeutics, Inc., AILERON THERAPEUTICS INC, Altimmune, Inc., Aerpio Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., PROTEOSTASIS THERAPEUTICS, INC., Tokai Pharmaceuticals Inc, Marina Biotech, Inc., MOMENTA PHARMACEUTICALS INC, ALNYLAM PHARMACEUTICALS, INC., EON LABS INC, IDENIX PHARMACEUTICALS INC, CHIRON CORP, and PRECISION BIOSCIENCES INC.
SEC CIK
NOVARTIS AG's CIK is 0001114448
Past Insider Trading and Trends
2012 was NOVARTIS AG's most active year for acquiring shares with 19 total transactions. NOVARTIS AG's most active month to acquire stocks was the month of January. 2011 was NOVARTIS AG's most active year for disposing of shares, totalling 79 transactions. NOVARTIS AG's most active month to dispose stocks was the month of December. 2005 saw NOVARTIS AG paying a total of $405,141,038.65 for 12,022,776 shares, this is the most they've acquired in one year. In 2014 NOVARTIS AG cashed out on 78,558,820 shares for a total of $816,566,346.40, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Cellular Biomedicine Group, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Poseida Therapeutics, Inc. (PSTX) Snapshot price: $3.79
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 5.91M |
—
|
—
| 5.91M |
Jul 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Akouos, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.18M |
$17.00 |
—
| 1.18M |
Jun 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Forma Therapeutics Holdings, Inc., No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Galera Therapeutics, Inc. (GRTX) Snapshot price: $0.1729
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -28.88% | -1.00M |
$8.25 | -$8,268,960.00 | 2.47M |
Jun 18 - Jun 19
| |||
Form 4
| -0.56% | -19.39K |
$9.21 | -$178,610.14 | 3.47M |
Jun 15 - Jun 17
| |||
Form 4
| -0.49% | -17.23K |
$9.33 | -$160,809.72 | 3.49M |
Jun 10 - Jun 12
| |||
Form 4
| -0.60% | -21.31K |
$9.57 | -$203,904.26 | 3.51M |
Jun 5 - Jun 9
| |||
Form 4
| -0.42% | -14.96K |
$9.68 | -$144,850.56 | 3.53M |
Jun 2 - Jun 4
| |||
Form 4
|
∞
| 3.54M |
$12.00 |
—
| 3.54M |
Nov 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |